Olanzapine and warfarin drug interaction

J. F. Maya, J. T. Callaghan, R. F. Bergstrom, B. J. Cerimele, K. Kassahun, E. H. Nyhart, D. C. Brater

Research output: Contribution to journalArticle

2 Scopus citations


An interaction study in 15 males was conducted between olanzapine (OL), an atypical antipsychotic, and warfarin (W) as a 3-way randomized crossover. The S-isomer of W is a probe for CYP2C9 metabolism. Each subject ingested 10mg OL or 20mg (R/S) W alone, and OL+W combination (OL+) as single doses (10 day washout interposed). OL+ did not potentiate adverse events of OL or W or anticoagulant effects of W. Stereo specific assays for RW and SW (HPLC-UV) and OL (HPLC-EC) were done. RW, SW and OL noncompartmental pharmacokinetics (PK) were assessed. Statistical evaluation by ANOVA for crossover design showed no significant (p>0.05) differences between OL or W versus OL+. PK Variables OL OL+ RW RW+ SW SW+ Cmax ng/mL 10.7 9.5 1280 1210 1330 1250 T1/2 hr 27.9 30.0 37.7 39.0 131.3 31.3 AUCμg×hr/mL .377 .353 48.5 47.4 36.3 35.8 CL/FF L/hr 29.8 30.9 0.21 0.22 0.28 0.29 Vβ/FF L 1150 1300 11.4 12.0 12.6 12.7 W PK were unaffected by concomitant OL and vice versa. OL does not inhibit CYP2C9.

Original languageEnglish (US)
Number of pages1
JournalClinical Pharmacology and Therapeutics
Issue number2
StatePublished - Dec 1 1997

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Olanzapine and warfarin drug interaction'. Together they form a unique fingerprint.

  • Cite this

    Maya, J. F., Callaghan, J. T., Bergstrom, R. F., Cerimele, B. J., Kassahun, K., Nyhart, E. H., & Brater, D. C. (1997). Olanzapine and warfarin drug interaction. Clinical Pharmacology and Therapeutics, 61(2).